Inhibrx (INBX)

• Market cap: $886M
• 1 day: -6.09%
• 5 days: -11.34%
• 1 month: -22.53%
• 3 months: -30.39%
• 6 months: 124.63%
• Year to date: -18.82%
• 1 year: 332.06%
• 5 years: 386.97%
• 10 years: 386.97%
• Sector: Healthcare
• Industry: Biotechnology

About: Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.

Employees: 161